BMY Bristol-Myers Squibb Co.

$BMY $VKTX BL will not sell. It is obvious now. He will partner for the right deal. And agree BMY as desperate as novo. $NVO holders - some clueless and trash VK not realizing VK is a gift from heaven to save their company. Although I honestly believe when it is heated and the offer is close to final .: BMY , $ABBV or even Lilly will not make it easy on novo and they may snatch the deal.

$BMY $SLS Part 2. GPS is an immunotherapy that trains the patient's own immune system to hunt down residual cancer cells expressing the WT1 protein. GPS offers a "favorable" profile because it targets cancer cells specifically with minimal toxicity - because it is an immunotherapeutic, side effects are primarily low-grade local injection site reactions (redness/mild pain). • No Myelosuppression: Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. • Preserved Quality of Life: Patients generally do not experience the daily fatigue or GI distress associated with oral maintenance chemotherapy. While Onureg is FDA-approved for CR1 (first remission), GPS has shown compelling data both in CR1 as well as in the more difficult-to-treat CR2 (second remission) setting, where prognosis is typically dire. ✌️🙏❤️‍🩹

$BMY $SLS Part 3. • In the QUAZAR trial (first remission), Onureg extended Overall Survival (OS) to ~24.7 months vs. 14.8 months (placebo). GPS, in CR1, showed a median OS of 67.6 months and in patients 60 years and older, who make up most AML patients, a median OS of 35.5 months. • In Phase 2 studies for patients in second remission (CR2)—a population with historically poorer outcomes than CR1-GPS demonstrated a median OS of ~21 months compared to historically expected 6-8 months with best available therapy. GPS induces a specific T-cell response in nearly all patients. ****This is before Ad Infinitum Dosage***** 🤯 Data suggests that patients who mount a strong immune response may achieve significantly prolonged remission, effectively keeping the leukemia "dormant" via immune surveillance. ✌️🙏❤️‍🩹

$BMY Leerink downgraded Bristol Myers to Market Perform from Outperform and cut its target to 59 from 73, days after the same firm upgraded the stock on AbbVie’s emraclidine failure. The flip is the interesting part. A deeper look at the pipeline left analyst David Risinger short on conviction ahead of the next several readouts: admilparant Phase 3 could disappoint on efficacy or safety, milvexian may not hold up head-to-head against Eliquis in atrial fibrillation, and Cobenfy adoption in Alzheimer's psychosis could be slow even on a Phase 3 win, with providers reaching for off-label generics. Last week Cobenfy was the upgrade thesis. This week its commercial path is the reason to step back. Shares fell about 3.5% Monday. Street consensus is still a Moderate Buy with a 67 average target. Tracking the pipeline readouts.

$BMY Bristol Myers Squibb on clear support here around $63. HSBC price target raised from $60 to $65 ⬆️

$BMY I find it comical when analysts raise their price targets on a stock even though it's almost $20 higher than the target is currently. And then they raise it a buck to say "yea we were off a bit so here's a dollar raise......"

$BMY Camzyos just became the only FDA-approved therapy for obstructive HCM in a pediatric population. Wednesday's approval extends the label to adults and kids weighing at least 30 kg (66 lb), based on the Phase 3 SCOUT-HCM trial in 44 adolescents aged 12 to under 18 with NYHA class 2 or 3 disease. At week 28, the Valsalva LVOT gradient fell 48.5 mm Hg on mavacamten vs 0.5 mm Hg on placebo, a 48.0 mm Hg difference (p less than .001). No patient on drug developed an ejection fraction below 50 percent, which was the safety read cardiologists were watching. Before this, adolescents were managed on beta blockers, calcium channel blockers, and disopyramide, with guidance largely extrapolated from adult data. BMS says Camzyos now has the broadest indication of any cardiac myosin inhibitor, and the trial data are published in NEJM.

$BMY discloses a fatal liver injury in its Phase 3 fibrosis program, according to Endpoints News.

$BMY | Snapshot 📊💊 • Business: Premier global biopharmaceutical leader specializing in innovative therapies across oncology, hematology, immunology, and cardiovascular diseases. • Financial Health & Pipeline: Strong dividend yield and stable free cash flow driving strategic pipeline acquisitions and late-stage clinical trial execution.• Bias & Conviction: Pullback Support Watch | Moderate Conviction (Watching for stabilization at $62.04 support for a continuation entry). 🎯 Key Levels: 🐂 Bull Trigger: $63.75 / $65.67 🚀 Targets: $65.67 / $67.00 / $68.64 🛡️ Support: $62.27 / $62.04 ⚠️ Risk: $60.00 / $58.09 🔥 Options Flow: • 🟢 06/17/2027 $65.0 Call ($227.5K Block | +2.56% OTM) • 🟢 06/17/2027 $70.0 Call ($74.2K Sweep | +9.26% OTM) • 🔴 01/21/2028 $55.0 Put ($163.8K Block | -14.25% OTM) • 🟢 10/16/2026 $65.0 Call ($33.8K Sweep | +0.98% OTM)